Hello, everyone, and how are you this morning? Another balmy day is unfolding here on the Pharmalot campus where the short person is sleeping in and the official mascot, as always, is scavenging for things to chew. As for us, we are turning to cups of hot stimulation as we mull over our to-do list. Meanwhile, we have assembled another laundry list of interesting items to help you along. So here is to a productive day. Hope you succeed, and, of course, do stay in touch. …

The National Institutes of Health may own intellectual property that undergirds a leading Covid-19 vaccine being developed by Moderna (MRNA), according to documents obtained by Axios and an analysis from Public Citizen. The documents suggest that the U.S. government has an actual stake in the vaccine and could try to make the vaccine a free or low-cost public good with wide distribution, if the product turns out to be safe and effective.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy